<b>Methods</b>: As a preliminary investigation, this prospective single-centre pilot study enrols 43 patients, categorised into: obstructive hypertrophic cardiomyopathy (<i>n</i> = 19), transthyretin cardiac amyloidosis (<i>n</i> = 15), or preserved-ejection-fraction hypertrophic phenotypes (<i>n</i> = 9). This evidence concerns the gene TTR and cardiac amyloidosis.